Peter J Leary
Overview
Explore the profile of Peter J Leary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Leary P, Le R, Panjabi S, Hartney J, Goyal A, Ward C, et al.
Am J Respir Crit Care Med
. 2025 Jan;
PMID: 39836217
Rationale: Guidelines recommend patients with pulmonary arterial hypertension (PAH) be referred to pulmonary hypertension (PH) centers, but little is known about where care is actually delivered in the United States...
3.
Leary P, Rayner S, Branch K, Hogl L, Liston N, Barros L, et al.
Chest
. 2025 Jan;
PMID: 39761829
Background: Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in...
4.
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)
Forbes L, Bauer N, Bhadra A, Bogaard H, Choudhary G, Goss K, et al.
Pulm Circ
. 2025 Jan;
15(1):e70027.
PMID: 39749110
Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor,...
5.
Pi H, Xia L, Boucherat O, Suresh K, Hemnes A, Bonnet S, et al.
Circ Heart Fail
. 2024 Oct;
17(11):e012067.
PMID: 39435559
Background: Pulmonary arterial hypertension (PAH) is a disease of progressive right ventricular (RV) failure with high morbidity and mortality. Our goal is to investigate proteomic features and pathways associated with...
6.
Rayner S, Tedford R, Leary P, Mak S, Houston B
Am J Respir Crit Care Med
. 2024 Apr;
210(6):712-714.
PMID: 38668713
No abstract available.
7.
Philip N, Yun X, Pi H, Murray S, Hill Z, Fonticella J, et al.
Am J Physiol Lung Cell Mol Physiol
. 2024 Jan;
326(3):L252-L265.
PMID: 38226418
Pulmonary arterial hypertension (PAH) is a morbid disease characterized by significant lung endothelial cell (EC) dysfunction. Prior work has shown that microvascular endothelial cells (MVECs) isolated from animals with experimental...
8.
Oppegard L, Barros L, Pi H, Kornfield J, Hough C, Rayner S, et al.
Pulm Circ
. 2023 Nov;
13(4):e12308.
PMID: 38027456
Relationships between obesity and outcomes in pulmonary arterial hypertension (PAH) are complex. Previous work suggested obesity, occurring alongside PAH, may be associated with better survival. In our work, we suggest...
9.
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension due to septic emboli
Steinberg Z, Rayner S, Leary P
Catheter Cardiovasc Interv
. 2023 Nov;
103(1):115-118.
PMID: 37994384
We present the case of a 28-year-old woman with a history of tricuspid valve endocarditis leading to chronic thromboembolic pulmonary hypertension (CTEPH) with multiple pulmonary artery chronic total occlusions (CTOs)...
10.
Fling C, De Marco T, Kime N, Lammi M, Oppegard L, Ryan J, et al.
Ann Am Thorac Soc
. 2023 Sep;
20(12):1718-1725.
PMID: 37683277
Pulmonary arterial hypertension (PAH) is a heterogeneous disease within a complex diagnostic and treatment environment. Other complex heart and lung diseases have substantial regional variation in characteristics and outcomes; however,...